Fig. 5: Anti-tumour activity of an engineered human KYNase enzyme. | Nature Catalysis

Fig. 5: Anti-tumour activity of an engineered human KYNase enzyme.

From: Bypassing evolutionary dead ends and switching the rate-limiting step of a human immunotherapeutic enzyme

Fig. 5

Time course of CT26 colon carcinoma tumour volumes treated with either vehicle, HsKYNase_95 or anti-PD-1 antibody (n = 8 mice for each experimental arm). The data are presented as means ± s.e.m. Statistical significance was determined by unpaired t-test (two tailed). *P < 0.05 comparing HsKYNase_95 treatment with the vehicle control. The inset shows steady-state kinetics parameters and residual activity after incubation in serum for HsKYNase_66 and HsKYNase_95.

Source data

Back to article page